Harbin Pharmaceutical Group: The affiliated company received the approval notice for the listing application of chemical raw materials.

2026-02-22 05:12:48

Abstract generation in progress

Haya Pharmaceutical Co., Ltd. announced that its subsidiary, Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd., has received the “Approval Notice for the Marketing Application of the Chemical Raw Material Drug” for Iron Protein Succinate from the National Medical Products Administration (Approval No.: 2026YS00100). Iron Protein Succinate is an organic iron compound. The approval of the marketing application for this raw material drug indicates that it has met the relevant technical standards for drug review in China. According to the National Medical Products Administration Drug Review Center website, as of the date of this announcement, there are 11 domestic companies with registration status “A” for Iron Protein Succinate raw material drugs, including Harbin Pharmaceutical Group Sanjing Ming Shui Pharmaceutical Co., Ltd., Jichuan Pharmaceutical Group Co., Ltd., and others.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes